anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new composition for treating GERD (gastroesophageal reflex disease).  &lt;P&gt;SOLUTION: The composition for preventing and/or treating gastroesophageal reflex disease comprises theanine. The composition is used in a food or a medicine. The method for preventing and/or treating gastroesophageal reflex disease comprises administration of theanine-containing composition. Theanine is used for producing a food or a medicine to be applied to an individual having gastroesophageal reflex disease.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Kinase-targeted covalent inhibitors are usually irreversibly targeting noncatalytic cysteines in the ATP-binding site. These compounds are designed by directly introducing an electrophile on a reversible-inhibitor scaffold. Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads), targeting a solvent exposed cysteine at &gt;10 Å from the core reversible inhibitor. A variety of novel linkers have been designed and used to link the warhead with the reversible scaffold. We disclose a novel chemical space for drug-like covalent modifiers of phosphoinositide 3-kinase alpha (PI3Kα), an enzyme frequently altered in human malignancies. The invention relates to novel covalent inhibitors showing higher in vitro affinity, cellular potency and improved metabolic stability (rat liver microsomes). The compounds of the invention could be exploited as therapeutic agents and chemical probes useful for modulating cellular activities such as signal transduction, proliferation, differentiation and cell death.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compositions and methods for the construction of nucleic acids comprising all or a portion of a viral genome.  &lt;P&gt;SOLUTION: The recombinant viral genome may be constructed to contain multiple recombination and/or topoisomerase recognition sites. The compositions include vectors having multiple recombination sites with unique specificity that contain all or a portion of a viral genome. The methods permit the insertion of a sequence of interest into a viral genome using recombinational and/or topoisomerase-mediated cloning. There are also provided methods of constructing recombinant virus, methods of expressing polypeptides, and methods of expressing fusion polypeptides.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The present invention is related to the field of immunology, particularly the generation and selection of monoclonal antibodies (mAbs) against gangliosides (Abls) which antibodies are specific, have recurrent idiotypes and have value as immunoregulators of the immune response against those antigens, and to obtaininganti-idiotypic mAbs (Ab2s) generated by the immunization with the said anti ganglioside mAbs. Accordingly, an objective of this invention is to provide anti ganglioside mAbs (Abls) with idiotypes capable of inducing an antigen specific response (Abl&#39;) in the absence of the antigen and the methods for its generation. Another objective of this invention is to provide anti-idiotypic mAbs (Ab2s) generated by immunization with anti ganglioside mAbs that have the above mentioned property and also capable of producing all Abl&#39; response. A further objective of the invention comprises generating specific anti ganglioside mAbs (Abl, immunizing mice and other species with said antibodies and selecting those antibodies capable of generating an antigen specific response (Abl&#39;): generating anti-idiotypic mAbs by immunizing mice or other animal species with aforementioned anti ganglioside mAbs. It will be understood that where the term antibodies is used herein that fragments, derivatives and the like which have similar antigen grinding properties are also intended. Many ways of arriving at derivatives and/or fragments are known in the Art. Ways of producing derivatives and/or fragments include but are not limited to chemical cleavage and/or (re) assembly, recombinant production of single chain antibodies and/or molecular recognition units (MRU&#39;s), CDR-grafting class switches, etc.
PURPOSE:To obtain the titled emulsion by adding a specific radically polymerizable monomer and an ultraviolet absorber to an emulsion of an emulsion-polymerized polymer which may contain an ultra-violet absorber and carrying out the emulsion polymerization of the monomer. CONSTITUTION:An emulsion of an emulsion-polymerized polymer is added with at least one kind of radically polymerizable monomer [e.g. carboxyl- containing monivinyl monomer (a non-film-forming resin capable of improving water resistance, etc., can be produced by using acrylic acid, etc., in an amount of &lt;5wt% of the whole monomer), monovinyl ether, polyfunctional crosslinking monomer, etc. - or + capable of forming a polymer having a contact angle to water of larger than that of the emulsion polymer by 1-110 deg.. The emulsion is emulsion-polymerized to obtain an emulsion of a non-film-forming resin having small pores in the resin and containing an ulraviolet absorber (e.g. 2-ethylhexyl- p-dimethylaminobenzoate). The emulsion prevents transient dermatic stimulation, has high safety and contains the ultra-violet absorber in stable state.
Apparatus and method are provided to collect and analyze phonocardiogram (PCG) an electrocardiogram (ECG) waveforms. In one novel aspect, the PCG and ECG waveforms are collected from wearable devices. In one embodiment, the wearable device collects heartbeat waveforms by attaching the device to the patient for a long period and sends the collected waveforms to a receiver through a wireless network. In one embodiment, an acoustic seal layer is attached to the wearable device to reduce the body movement noises and environmental noises. In another novel aspect, an analysis method compares received patient&#39;s current PCG/ECG waveform with historic data. In one embodiment, the historic data are stored in a cloud-based database.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for maintaining an activity of BMP-2 (bone morphonogenetic protein-2) and to provide an agent to which the method is applied.  &lt;P&gt;SOLUTION: The method for maintaining the activity of BMP-2 is characterized in that HS (heparan sulfate) and/or Hep (heparin) are made to coexist. An activity maintaining agent for the BMP-2 comprising the HS and/or Hep as active ingredients is provided. A cell proliferation promoter and/or a cell differentiation promoter comprising the HS and/or Hep as the active ingredients are provided. The cell is preferably one or two or more cells selected from the group consisting of osteoblasts, chondroblasts, cementoblasts, mesenchymal stem cells derived from bone marrow and cells derived from periodontal ligaments. The cell proliferation promoter is preferably used as an osteogenesis promoter or a regeneration promoter for bones or cartilages. Furthermore, the cell proliferation promoter is more preferably used as the osteogenesis promoter or the regeneration promoter for periodontal tissues.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a human testis-specific kinase (tssk) gene family as target genes for contraceptives, and to provide a protein corresponding to the gene family.  &lt;P&gt;SOLUTION: The testis-specific kinase family (tssk family) is provided. A nucleic acid sequence encoding the testis-specific kinase and an antibody against the kinase are also provided. Furthermore, the use of the kinase as a target for isolating a specific inhibitor or as an antagonist of the tssk kinase activity is provided. The inhibitor is expected to be used as a contraceptive.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
NEW MATERIAL:Phycocyanin pigment A which is a blue pigment protein having properties of the maximum absorption wavelength at 610-620nm and a structure of a ring opened tetrapyrrole linked to a protein, present in a blue-green alga growing at &gt;=45 deg.C, having -5-80 deg.C stable temperature range of the pigment, 2-9 stable pH range of the pigment, 7 optimum pH, constituted of alpha and betasubunits having 18,000+ or -1,000mol.wt. of the pigment protein and having 450-750nm absorption wavelength spectrum, e.g. Fig.1. USE:A colorant for foods, cosmetics and medicines. PREPARATION:A thermophilic blue-green alga, e.g. the genus Synechoccus, growing at &gt;=45 deg.C is transplanted to BG-1 culture medium shown in the table at 1% vol./vol., irradiated with light at 1,000-10,000 lux and cultivated at 30-65 deg.C for 1-2 weeks. The microbial cells are then collected by centrifugation, freeze-dried and added to a buffer solution at 4-7pH to extract the pigment. The resultant extract solution is then purified by salting out, dialysis, etc.
The invention discloses healthy tea for treating prostatitis. The healthy tea is prepared from the following raw materials by weight: 7 to 9g of codonopsis pilosula, 7 to 9g of astragalus, 7 to 9g of plantain seed, 7 to 9g of root of rehmannia, 7 to 9g of golden thread, 7 to 9g of cattail pollen, 7 to 9g of twotooth achyranthes and 3 to 5g of Pu&#39;er tea. Optimally, the healthy tea comprise the following raw materials by weight: 8g of codonopsis pilosula, 8g of astragalus, 8g of plantain seed, 8g of root of rehmannia, 8g of golden thread, 8g of cattail pollen, 8g of twotooth achyranthes and 4g of Pu&#39;er tea. The weight of each component in the formula represents a propotional relationship. The healthy tea is prepared by the following steps of: slightly frying the raw material medicaments according to a certain proportion; drying at the temperature of 60 DEG C; crushing, mixing and uniformly stirring; packaging 3g of the mixture into each bag; and sealing and packing products. The Chinese herbal medicines have the effects of benefiting vital energy, detoxicating and disinhibiting dampness, and activating blood and dissolving stasis by organic combination, diagnosis and treatment and mutual complementation so as to fulfill the aim of treating the prostatitis.
FIELD: experimental medicine. SUBSTANCE: one should isolate burnt skin at area of not less than 30% against total skin surface due to making two encircling full-layer incision up to surface fascia along burn&#39;s edge. Then skin and subcutaneous fiber should be removed from surface fascia as a single complex by internal wound&#39;s edge in the form of cylindrical tube by turning internal lateral surface out. Turned edge is replaced longitudinally till complete separation of burnt tissues. Then, after hemostasis, one should put animal&#39;s body, except its head, into a tank with periodically renewed sterile saline aqueous solution. Solution&#39;s temperature corresponds to 36.8 C. Saline solution is supplemented with combination of chemotherapeutic preparations. The method enables to prolong and improve life period in experimental animals. EFFECT: higher efficiency of therapy. 1 cl, 1 ex
1,207,372. Aryl sulphones. ROUSSEL UCLAF. 29 Aug., 1967 [26 Aug., 1966(2); 24 Feb., 1967; 16 June, 1967; 19 July, 1967], No. 8367/70. Divided out of 1,207,371. Heading C2C. The invention comprises aryl sulphones of the general formula: H-A-SO 2 -Ar wherein Ar is an aryl group having either one or two aromatic rings which may be substituted with one or more C 1 -C 2  alkyl, alkoxy, halogenomethyl and/or nitro groups or halogen atoms and A is either the radical: or the radical: or the radical in which R 1  is a hydrogen atom or a lower C 1 -C 4  alkyl radical, R 2  and R 3  which may be the same or different are each alkyl, aralkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or heterocyclic radical, R 3  having at least 2 carbon atoms, or R 2  and R 3  together with the intervening carbon atom form a saturated carbocyclic ring with 3 to 7 carbon atoms or an unsaturated carbocyclic ring, e.g. a cyclohexene or cyclopentadiene ring, such carbocyclic rings if desired being substituted by one or more methyl, ethyl and/or methoxy or ethoxy groups, or R 2  and R 3  together with the intervening carbon atom form a polynuclear aromatic system such as fluorene, or a heterocycle which may be substituted by one or more methyl, ethyl and/or methoxy or ethoxy groups, R 4  is a methyl or ethyl group, R 5  is a hydrogen atom or methyl or ethyl group, or R 4  and R 5  form together with the two intervening carbon atoms a saturated or unsaturated heterocyclic or carbocyclic ring, Y is -CH 2 - or a saturated or unsaturated aliphatic hydrocarbon chain and Y&lt;SP&gt;1&lt;/SP&gt; is a methine group or a saturated or unsaturated aliphatic hydrocarbon chain. They may be obtained by reacting ArSO 2 M wherein M is an alkali metal, e.g. Na or K, with an allylic type derivative HAX wherein X is Cl, Br or I or a methane sulphonyloxy or toluene-psulphonyloxy group, advantageously in the presence of a solvent and in the presence of a basic reagent. In a modification the products are obtained by reacting the compounds ArSO 2 M with an alcohol HA-OH in the presence of formic acid. 3 - Ethyl - 1 - penten - 3 - ol is obtained from the reaction of pentan-3-one with vinyl magnesium chloride in tetrahydrofuran and then treating with water and is converted into 1 - bromo - 3 - ethyl - 2 - pentene by reaction with PBr 3  in petroleum ether. Several other analogous unsaturated alcohols and unsaturated bromo compounds of the type HABr are also specified and are obtained similarly starting with the appropriate unsaturated ketone. 3 - Methyl - 2 - cyclohexen - 1 - ol is obtained by the action of lithium aluminium hydride on 3-methyl-2-cyclohexen- 1-one in tetrahydrofuran.
PROBLEM TO BE SOLVED: To obtain a composition for treatment of restenosis by including a pharmaceutically effective amount of a complex of heparan or heparin sulfate and dermatan sulfate together with a support. SOLUTION: This composition for treatment of restenosis is obtained by including (A) a pharmaceutically effective amount of a complex of heparan or heparin sulfate and dermatan sulfate (pref. in the weight ratio of the heparan or heparin sulfate to dermatan sulfate of &gt;1, more pref. about 8:2, in particular sulodexide) together with (B) a pharmaceutically acceptable support (pref. suitable for the sustained release of the ingredient A, in particular a biomedical device such as a coil, artificial valve, blood vessel graft or stent). The restenosis as the objects for the treatment using this composition are pref. such ones as to be resulted from medical treatments including percutaneous intubation coronary artery plasty, atheroma excision, laser blood vessel plasty, arterial bypass transplantation, and cardiac transplantation.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to radiation diagnostics, urology and oncology, can be used for diagnostics of prostate. Perfusion computer tomography of prostate is performed. First, performing scanning in native mode. Upper limit of scanning passes along the upper contour of wings of iliac bones, the lower border – along the lower outline of ischial tuberosity. Then, on the obtained native images, sections are marked for subsequent perfusion scanning of the prostate: the initial scanning edge corresponds to a prostate base-level cut with overlapping of seminal vesicles, end section – to level of an apex of a gland. Volume of the contrast agent is calculated on basis of 0.3 g of iodine per 1 kg of the patient&#39;s weight. To construct perfusion maps, starting points are chosen – ellipse ROI: first point – to large arterial vessel, second – to prostate tissue. After that, calculation is performed in automatic mode with subsequent construction of functional maps. Calcificate, metal fragments and gas are not included in the zone of interest. Applied ellipse should not extend beyond the contrasted lumen of a vessel or tissue of the gland. Thereafter, on the functional maps obtained in the central and peripheral zones, at the level of the apex, base and in middle 1/3 gland, the regional blood flow values are determined on both sides: the volume of the regional blood flow (Blood Volume – BV), mean time of passage of blood (Mean Transit Time (MTT), rate of regional blood flow (Blood Flow – BF). At BF 27.96±6.3 ml/100 g/min, BV 3.51±1.0 ml/100 g and MTT 1.4±0.6 s diagnose prostate adenoma. At BF 52.05±9.14 ml/100 g/min, BV 8.4±0.74 ml/100 g and MTT 14.0±0.5 s is diagnosed with prostate adenocarcinoma. Nonionic iodine-containing radiopaque agents with active substance concentration of 350 or 370 mg/ml can be used.EFFECT: method provides higher accuracy of examination, possibility of its carrying out in the presence of contraindications to MRI by differentiation of new growths of prostate when calculating BV, MTT and BF values for adenoma and adenocarcinoma of prostate.1 cl, 8 dwg, 2 ex
Present disclosure relates to a patient response device. Patient response device includes: a processor controlling operations of patient response device, a network interface controller facilitating communication among patient response device, an emergency response system server and a communication system of an emergency response system, an emergency medicine storage, and a non-volatile memory. Emergency medicine storage includes one or more emergency medicine compartments for storing one or more patient specific emergency medicines for patients. Non-volatile memory stores an operating system, a GPS module for detecting GPS location of patient carrying patient response device, and a patient response device controller. Patient response device controller includes: a patient information storage module, a patient communication control module, and computer executable instructions. Patient information storage module stores patient&#39;s information. Patient communication control module facilitates communication through the network interface controller to the emergency response system server and the communication system over a communication network.
PROBLEM TO BE SOLVED: To provide a method for preparing cleansing lotion hardly causing skin trouble, and having a moisture-preserving activities not to dry the skin after washing the face. SOLUTION: An organic acid of &gt;=10&lt;-4&gt; mol/L and an organic acid salt of &gt;=10&lt;-3&gt; mol/L are added to an aqueous solution containing a reducing agent having activities for removing free chlorine added thereto to prepare the aqueous solution. The obtained aqueous solution is subjected to an electrolysis. The pH of the aqueous solution is almost unchanged before and after the electrolysis in the range of 4. 5-6. 5. The oxidation-reduction potential of the oxidation- reduction system comprising an oxidant and a reductant included in the aqueous solution is lowered from the state before the electrolysis to the state after the electrolysis.
PURPOSE: To obtain a composition for intrabuccal use effective against plaque, capable of controlling decalcification of dental enamel, comprising a chlorous acid liberating compound, a protonic acid and an anti-decalcification agent. CONSTITUTION: This composition for intrabuccal use is obtained by mixing 0.-01-10wt.% of a chlorous acid liberating compound (e.g. sodium chlorite) with 0.01-6wt.% of a protonic acid, an anti-decalcification agent (e.g. indium (III)) and a carrier such as a dentifrice and a mouth washing solution and preparing. The composition can be prepared into a dosage form such as toothpaste and oral liquid composition. The amount of the protonic acid is an amount to adjust the composition to pH&lt;=5.5 and to buffer the composition. Citric acid, malic acid, etc., are cited as the protonic acid. The composition for oral cavity has no trouble to the surface of hard tissue of oral cavity.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent a leakage of privacy information in a system for managing a processing history to which different management objects mutually relate.  &lt;P&gt;SOLUTION: A wireless tag unit 110 storing secret diagnostic treatment agent ID information, in which diagnostic treatment agent ID information for identifying a diagnostic treatment agent is made secret, is attached to the diagnostic treatment agent concerned, and also, a barcode presentation portion 120 capable of outputting patient ID information, etc. for identifying a patient is attached to the patient concerned. Here, the secret diagnostic treatment agent ID information in the wireless tag unit 110 is updated at the time determined by an arbitrary set condition. Then, when a treatment action is taken to the patient to which the diagnostic treatment agent is used, a database indicating the treatment history is implemented using the secret diagnostic treatment agent ID information, being read out from the wireless tag unit 110 attached to the diagnostic treatment agent concerned, and patient ID information, being read from the barcode presentation portion 120 attached to the patient concerned.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
NEW MATERIAL:A peptide of formula I (A is H or organic residue reactive with amino group; pro is L-proline; n is an integer &gt;=3). EXAMPLE:The compound of formula II (St is stearoyl). USE:An additive for a cosmetic, having improved beautifying effects on the skin, e.g. prevention of fine wrinkles and aging of the skin, with high safety without irritant action on the skin, improved cosmetic effects, e.g. adhesiveness to the skin, covering power of the skin surface and feeling of use, and good storage stability. The amount of the additive is 0.001-1wt% in a basic cosmetic material and a base material for a makeup cosmetic, e.g. a milky lotion, lotion, face powder or lipstick. PROCESS:The peptide of formula I is obtained by protecting the amino or carboxyl group which will not participate in the reaction of the raw material amino acid or peptide, and condensing the protected amino acid or peptide.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of simply using, free from adverse effects even when used for a long period, being inexpensive, having beautifying and whitening action and capable of imparting gloss to skin and hair by using water extract of soil collected from a specific stratum as an active ingredient. SOLUTION: This composition for cosmetic is obtained by using water extract of humus of Pteridophyta collected from ancient stratum. An extract having the following properties is preferably used as the extract. pH, 3.5±0.5; density, 1.003g/cm&lt;3&gt; ; boiling point, 103 deg.C; nearly colorless and transparent, slightly sour and odorless; amino acid content, &lt;225μg/1; mineral content, 216.3ppm; viable cell number of bacteria, &lt;=300/g; E.coli group, negative; acute toxicity, zero; irritation to skin, slight. The water extract exhibits beautifying and whitening effect by tyrosinase activity inhibiting action. The cosmetic composition can be used as skin lotion, cream, milky lotion, pack, cosmetic, etc., for hair.
Purified water is obtained from tap water. NaCl is added to the purified water so that the conductivity thereof is at least 100 muS/cm. Then, electrolysis is applied. The obtained cathode water is output and neutralized. The obtained cathode water includes dissolved hydrogen (H&lt;+&gt;, H., H2) of at least 0.1 ppm. This dissolved hydrogen prevents or suppresses DNA damage.
FIELD: pharmaceutical industry, antibiotics. SUBSTANCE: invention relates to a technology of preparing erythromycin phosphate that is a water-soluble form of erythromycin. Method involves the suspension of erythromycin base in water, suspension acidification at temperature from 4 C to 7 C with ortho-phosphoric acid solution in mass part 5% up to pH value of obtained solution from 6.4 to 6.6. Then method involves sterile filtration and lyophilic drying by freezing an erythromycin phosphate solution at temperature from 30 C to 35 C and drying under deep vacuum by step-by-step increase of temperature of a heat carrier from 20 C to +60 C. The drying is performed at the heating rate preferably 14 C/h, not above. The novel method provides the quality enhancement of erythromycin phosphate by an index &#34;the content of anhydroerythromycine&#34; 1.5%. EFFECT: improved method of preparing, enhanced quality. 2 cl, 1 ex